

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



08th May, 2017

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

To,
**National Stock Exchange of India
Limited**
“Exchange Plaza”,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051

Sub: Audited Financial Results for the Quarter and year ended on 31st March, 2017

Scrip Code: 532637
Symbol: MANGALAM

Dear Sir,

In terms of Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Audited Financial Results for the quarter and year ended 31st March, 2017 along with the Auditors Report of the said period in the prescribed form which have been taken on record and approved by the Board of Directors of the Company at its meeting held on 08th May, 2017 at Mumbai.

The report of Auditors is with unmodified opinion with respect to Audited financial results (Standalone) for the quarter and year ended 31st March, 2017. Declaration to that effect is also enclosed herewith.


Kindly note that the meeting of the Board of Directors commenced at 04.00 p.m and concluded at 05.20 p.m.

Further please note that the company has made necessary arrangement to publish the same in the newspapers as required under the Listing Regulations.

Kindly take the same in your records.

Thanking You,
Yours faithfully,
For **Mangalam Drugs & Organics Ltd**

Nikita Bavishi
Company Secretary.




Audited Financial Results for the Quarter and Year Ended 31st March 2017 approved and taken on record by the Board at their meeting dated 8th May 2017

Sr. No.	Particulars	(Rs. in Lacs)				
		Audited (Refer Note-3)	Unaudited		Audited	Audited
		Quarter ended			Year ended	Year Ended
		Previous 3 months ended in the current year	Corresponding 3months ended in the previous year	Current accounting year ended	Previous accounting year ended	
		31.3.17	31.12.16	31.3.16	31.03.17	31.03.16
A	PART I - STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2017					
1	Sales/Income from operation(Inclusive of Excise duty)	8754.84	8051.93	7357.15	31244.39	30314.84
2	Other Operating Income	5.30	5.91	11.17	19.26	13.89
3	Total Net Income from Operation	8760.14	8057.84	7368.32	31263.65	30328.73
4	Expenditure					
	(a) Increase / decrease in stock in trade & work in progress	1543.18	226.22	(417.77)	1556.91	(7.95)
	(b) Consumption of raw materials	3799.96	4570.39	4461.42	18190.96	20239.12
	(c) Excise duty & service tax recovered	463.93	361.93	302.09	955.83	812.66
	(c) Employees Cost	473.25	511.15	410.23	1852.28	1438.69
	(d) Depreciation	154.99	129.89	108.62	500.71	441.30
	(e) Other expenditure	1065.62	1169.28	1177.55	3871.44	4079.97
	(f) Total	7500.93	6968.86	6042.14	26928.13	27003.79
5	Profit(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	1259.21	1088.98	1326.18	4335.52	3324.94
6	Other income	1.19	3.65	(72.41)	6.37	5.84
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	1260.40	1092.63	1253.77	4341.89	3330.78
8	Finance Cost	310.77	228.00	277.03	1003.65	929.18
9	Profit(+)/Loss(-) from ordinary activities after Finance cost & Exceptional Items(7-8)	949.63	864.63	976.74	3338.24	2401.60
10	Exceptional Items	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	949.63	864.63	976.74	3338.24	2401.60
12	Tax Expenses(incl Deferred Tax less Mat Credit entitlement)	293.55	245.00	423.29	968.55	798.29
13	Net Profit(+)/Loss(-) after Tax (11-12)	656.08	619.63	553.45	2369.69	1603.31
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	656.08	619.63	553.45	2369.69	1603.31
16	Paid up Equity Share Capital (face value Rs.10/-each)	1582.82	1582.82	1437.82	1582.82	1437.82
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	7033.55	0.00	3866.36	7033.55	3866.36
18(i)	Earning per share (EPS) (before extraordinary items) (of Rs.10/- each) not annualised) :					
	(a) Basic	4.14	3.92	3.85	14.97	11.15
	(b) Diluted	4.14	3.92	3.50	14.97	10.13
18(ii)	Earning per share (EPS) (after extraordinary items) (of Rs.10/- each) not annualised) :					
	(a) Basic	4.14	3.92	3.85	14.97	11.15
	(b) Diluted	4.14	3.92	3.50	14.97	10.13
B	INVESTOR COMPLAINTS					
		QUARTER ENDED 31/03/2017				
	Pending at the beginning of the Quarter	Nil				
	Received During the Quarter	Nil				
	Disposed During the Quarter	Nil				
	Remaining resolved at the end of the Quarter	Nil				

Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 8th May 2017
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk drugs" the disclosure requirement of Accounting Standard(AS-17)"Segment Reporting" is not applicable.
- The results for the quarter ended March 31,2017 are derived figures arrived at by subtracting the results for the nine months ended on December 31,2016 from the audited results for the year ended March 31,2017
- Previous year figure are regrouped wherever necessary.

Place: Mumbai
Date: 08.05.2017



For MILWANI ASSOCIATES
Chartered Accountants
F.R.N.:106405W

Rakesh K. Milwani Proprietor
Membership No.: 036099

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)
Chairman & Managing Director
DIN:01240086



STATEMENT OF ASSETS & LIABILITIES




(Rs. In Lacs)

Particulars		As at 31 March, 2017	As at 31 March, 2016
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	1,582.82	1,437.82
	(b) Reserves and surplus	7,033.55	3,866.36
	(c) Money recd twds Share Warrants	-	848.25
	Sub Total -Shareholders Funds	8,616.37	6,152.43
2	Non-current liabilities		
	(a) Long-term borrowings	2,073.56	1,692.15
	(b) Deferred Tax Liabilities (Net)	1,015.34	844.89
	Sub Total -Non-Current Liabilities	3,088.90	2,537.04
3	Current liabilities		
	(a) Short-term borrowings	3,754.50	3,537.57
	(b) Trade payables	2,077.55	2,067.50
	(c) Other current liabilities	1,566.41	1,681.85
	Sub Total -Current Liabilities	7,398.46	7,286.92
	TOTAL	19,103.73	15,976.39
B	ASSETS		
1	I) Non-current assets		
	(a) Fixed Assets	9255.62	5911.70
	(b) Long-term loans and advances	116.27	99.31
	Sub Total -Non-Current Assets	9,371.89	6,011.01
2	Current assets		
	(a) Current Investments	24.39	24.01
	(b) Inventories	3,724.95	4,734.06
	(c) Trade receivables	3,975.07	3,014.43
	(d) Cash and cash equivalents	62.73	49.53
	(e) Short-term loans and advances	1,944.70	2,143.35
	Sub Total -Current Assets	9,731.84	9,965.38
	TOTAL	19,103.73	15,976.39

Notes: 1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Sri Govardhan M. Dhoot)
Chairman & Managing Director
(DIN:01240086)
Place: Mumbai
Date: 08.05.2017



18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel : 22036132 / 9821162679 E-mail: rakesh_milwani@hotmail.com

**Auditor's Report On Quarterly Financial Results and Year to Date Results of the
Company Pursuant to the Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirement) Regulations, 2015**

To
Board of Directors
Mangalam Drugs & Organics Ltd.,
Mumbai

We have audited the quarterly financial results of Mangalam Drugs & Organics Ltd., for the quarter ended 31st March 2017, and the year to date results for the period 1st April 2016 to 31st March 2017, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25/ Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



Contd....2/-



18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel. : 22036132 / 9821162679 E-mail: rakesh_milwani@hotmail.com

: 2 :

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 in this regard; and

(ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March 2017, as well as the year to date results for the period from 1st April 2016 to 31st March 2017.



For MILWANI ASSOCIATES
Chartered Accountants
F.R.N.:106405W

(CA Rakesh K. Milwani) Proprietor
Membership No.: 036099

(CA RAKESH K. MILWANI)

Proprietor: MILWANI ASSOCIATES

CHARTERED ACCOUNTANTS

Membership No.036099

Firm Registration No. 106405W

Place : Mumbai

Date : 8th May, 2017.

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



08th May, 2017

To,

BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400 001.

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
BandraKurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 532637

Symbol: MANGALAM

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements), Regulations, 2015

Dear Sir/Madam,

This is to declare that the Statutory Auditors of the Company i.e. Milwani Associates, Chartered Accountants (Firm Registration No. 106405W) have issued an Audit Report with unmodified opinions on Standalone Annual Audited Financial Results for the Year ended 31st March, 2017. Hence, provisions of "Statement on Impact of Audit Qualifications" are not applicable to the Company.

This declaration is issued in compliance with Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements)(Amendment) Regulations, 2016, as issued by the Securities and Exchange Board of India vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016.

Thanking you,

Yours faithfully,

For MANGALAM DRUGS & ORGANICS LTD.



Govardhan M. Dhoot
Managing Director
DIN: 01240086

